X
Email:
sales@ruixibiotech.com
Products classification
ABOUT US
Email:
sales@ruixibiotech.com
Tel.:
02988811435
Home > products > pharmaceutical-intermediates > nuclide-drug > lu-177-psma-i-t

Lu-177-PSMA-617

Lu-177-prostate-specific membrane antigen-617

Catalog # Pkg Size Price(USD) Quantity Buy this product
R-M2-10083 10mg inquiry

Product description

177Lu-PSMA-617 is a radioligand therapy for targeted treatment of prostate cancer, which precisely kills cancer cells by labeling PSMA antigens with beta rays, especially suitable for patients with metastatic castration resistant prostate cancer (mCRPC). Clinical studies have shown that this therapy can significantly prolong patient survival and reduce PSA levels, and suitable patients need to be screened through PSMA PET/CT screening. Multidisciplinary diagnosis and treatment centers have been established domestically to promote standardized application.

This product is only for scientific research and cannot be used on the human body.


Appearance N/A
Molecular weight N/A
Purity >90%
Solubility N/A
Molecular formula N/A
Storage -20℃, protected from light and moisture
Transportation 4-25℃ temperature for up to 1-3 weeks
Stability 1 year
Document

msds of Lu-177-PSMA-617
Related Product